KoSyne NeuroTech Completes Pre-A Round to Accelerate Clinical Translation of Brain-Computer Interface Neuromodulation Platform | Tong's Family
Recently, **KoSyne NeuroTech** (hereinafter referred to as "KoSyne NeuroTech"), a **Dongtou Family company** specializing in non-invasive brain-computer interfaces and neuromodulation, announced the completion of its **Pre-A funding round** — another key milestone following Dongtou Capital's exclusive angel round investment. **This round was led exclusively by Yunqi Capital, with the proceeds to be used primarily for core technology R&D, clinical translation, and global expansion.**
Background
Recently, KoSyne NeuroTech, a Dongtou Family company specializing in non-invasive brain-computer interfaces and neuromodulation, announced the completion of its Pre-A funding round — a key milestone following Dongtou Capital's exclusive angel-round investment. This round was led exclusively by Yunqi Capital, with proceeds directed primarily toward core technology R&D, clinical translation, and global expansion.
As a next-generation full-stack technology platform addressing neuroscience needs, KoSyne NeuroTech applies multi-dimensional brain signal decoding to ultrasound, magnetic, electrical, and optical modulation modalities, while deeply integrating AI across diagnosis, treatment, and management workflows. This creates a technical flywheel of continuous iteration between clinical data and intervention protocols, offering systematic solutions for diagnosing and treating brain function disorders.
On the clinical front, KoSyne NeuroTech has established deep research partnerships with the National Center for Mental Disorders. Early clinical exploration has achieved breakthrough progress: significant symptom improvement within short treatment cycles, demonstrating the rare high efficacy and leading potential in the non-invasive brain-computer interface field — results that have also attracted attention and recognition from top overseas institutions.
Following a "research — clinic — home" technology deployment path, the company is building a product matrix covering diverse scenarios, committed to delivering neuroscience solutions that combine clinical value with technological leadership for patients and users.
The completion of this funding round signals capital markets' strong recognition of KoSyne NeuroTech's technical moat and clinical value. Post-funding, the team will accelerate technology iteration and clinical translation while continuously strengthening core competitive barriers.
Going forward, the company will continue deepening its focus on brain-computer interaction and neuromodulation, with the goal of becoming a globally leading intelligent infrastructure platform for neuroscience — pushing frontier technologies from the laboratory into clinics and ultimately into homes.
ID: daltonventure
Long press to follow
Recommended Reading
